European Commission grants approval to the first Tocilizumab biosimilar - Video

Published On 2023-09-23T10:00:02+05:30 | Updated On 23 Sept 2023 2:48 PM IST

Overview

The European Commission has granted marketing authorization to Fresenius Kabi for its tocilizumab biosimilar, Tyenne. This marks the first approval of a tocilizumab biosimilar in Europe, as announced in a press release on September 19 by the manufacturer, Fresenius Kabi. Tyenne is indicated for treating various conditions, including rheumatoid arthritis, systemic juvenile idiopathic arthritis, juvenile idiopathic polyarthritis, giant cell arteritis, CAR-T cell-induced severe or life-threatening cytokine release syndrome and COVID-19.

The European Medicines Agency opinion letter has confirmed that Tyenne demonstrates "comparable quality, safety, and efficacy" to the reference product RoActemra (tocilizumab), an interleukin-6 receptor inhibitor that gained initial authorization in the European Union back in 2009. Tyenne will be available in two forms: a 162 mg/mL prefilled syringe for subcutaneous injection and a 20 mg/mL concentrate for a solution suitable for intravenous administration.

Company’s CEO Pierluigi Antonelli said, “Being on the cutting edge of proposing an affordable, high-quality, and safe tocilizumab treatment option to health care providers and patients living with autoimmune diseases is an exciting step in our mission to provide access to alternative treatment options.

Speakers

Isra Zaman

B.Sc Life Sciences, M.Sc Biotechnology, B.Ed

Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751